Start Date
October 31, 2012
Primary Completion Date
July 31, 2014
Study Completion Date
October 31, 2014
Carboplatin
Carboplatin AUC4 on day 1 of 21-day cycle, for a maximum of 6 cycles.
Gemcitabine
Gemcitabine escalations 800 and 1000 mg/m2 (as determined in phase I) on days 1 and 8 of a 21 day cycle, for a maximum of 6 cycles.
Carboplatin
Carboplatin AUC 4 on day 1 of a 21 day cycle, for a maximum of 6 cycles.
Gemcitabine
Gemcitabine 800 or 1000 mg/m2 (as determined in phase I) on days 1 and day 8 of 21-day cycle, for a maximum of 6 cycles.
BNC105P
BNC105P as determined in phase I, on days 2 and 9 of a 21 day cycle for a maximum of 6 cycles, followed by single agent maintenance BNC105P 16 mg/m2 for a maximum of 6 additional cycles.
Royal Prince Alfred Hospital, Sydney
Royal Brisbane and Women's Hospital, Brisbane
Christchurch Hospital, Christchurch
Peter MacCallum Cancer Centre, Melbourne
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
University of Chicago, Chicago
Lead Sponsor
Collaborators (1)
University of Sydney
OTHER
Australia New Zealand Gynaecological Oncology Group
OTHER
Bionomics Limited
INDUSTRY
Hoosier Cancer Research Network
OTHER